Detecting Cancer with a Blood Test: Universal DX’s Big Move
What Universal DX does:
Universal DX (UDX) is on a mission to transform cancer from a terrifying disease into something curable by catching it early. They use bioinformatics and multi-omics to read cancer’s unique DNA signals, aiming at the deadliest types like colorectal, lung, pancreatic, liver, and esophageal cancers.
FREE REMOTE JOB BOARD by Startup to Follow
Looking for exceptional global talent? Reach our community by posting your job for free. (Also, if you’re looking for your next challenge, you can find incredible opportunities there too).
What’s Currently Going on in the Industry?
The cancer screening market is massive—$20 billion a year in the U.S. alone—yet over 600,000 people still die from cancer annually. Early detection is key, especially for colorectal cancer, which is the second leading cause of cancer deaths. Even though colonoscopies are the “gold standard,” let’s be honest, no one’s thrilled about them. That's where UDX steps in with a less invasive, more futuristic approach.
Company Birth Story
Born in 2012, Universal DX is the brainchild of a diverse team obsessed with cracking cancer’s code. They didn’t just emerge from any garage; they were hatched in Silicon Valley at Singularity University (where the tech elite daydream about changing the world). With partners like Quest Diagnostics and Hologic, UDX built a scientific dream team—think oncologists and gastroenterologists from the U.S. and Europe.
SPONSOR
Brows Media is a creative video agency that works with startups to create custom, top-quality explainer videos at affordable prices. Get 10% off when you say Startup to Follow sent you!
The Solution
Let’s talk Signal-C®, UDX’s advanced blood test for colorectal cancer screening. Using next-gen sequencing and bioinformatics wizardry, it finds DNA fragments shed by cancer cells floating around in the bloodstream. The FDA premarket approval process has kicked off, and they’re aiming to recruit 15,000 patients by 2025 for clinical trials. So yeah, they’re not messing around.
Why You Should Try Them Out
Ever had a colonoscopy? Not exactly a highlight of anyone’s week. Signal-C® offers a blood test alternative that's convenient, non-invasive, and—according to the experts—highly accurate. If catching cancer early is the name of the game, this test is a game-changer.
FREE REMOTE JOB BOARD by Startup to Follow
Looking for exceptional global talent? Reach our community by posting your job for free. (Also, if you’re looking for your next challenge, you can find incredible opportunities there too).
Why You Should Invest
The cancer diagnostics market is huge and only getting bigger. As the second biggest cancer killer, colorectal cancer needs more accessible screening options. UDX’s Signal-C® test fits right into this lucrative and life-saving niche. Backed by major players like Quest Diagnostics and Olympus Innovation Ventures, UDX is poised to ride the wave of the next biotech revolution.
More From Startup to Follow
Find other amazing startups: startuptofollow.com
Follow us on: Twitter | LinkedIn | Facebook
Connect with us: Partnerships and Advertising